TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22249353
Drug: Tailored treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored treatment strategy using the Multiplate analyzer
Study: 18046053
Drug: Red Bull
Normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Bull energy drink (2 mg/kg body mass of caffeine)
Study: 8789567
Drug: Alcohol (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.2 g alcohol.kg‐1 body mass)
Study: 6803692
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg/day for 4 months)
Study: 26715522
Drug: Iron-treated group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-treated group (50 mg elemental iron/daily)
Study: 11386492
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/day)
Study: 15195691
Drug: Nicardipine solution
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine solution (20 mg)
Study: 2871952
Drug: Atropine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1.2 mg, i.v.)
Study: 2871952
Drug: Metoclopramide (MCP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (MCP, 10 mg, i.v.)
Study: 25601942
Drug: SA-14-14-2 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA-14-14-2 (single dose)
Study: 25601942
Drug: JENVAC (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: JENVAC (single dose)
Study: 25601942
Drug: JENVAC (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: JENVAC (2 doses)
Study: 11346336
Drug: Crossover from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover from 6.5 mg/m(2) per day to higher doses
Study: 11346336
Drug: 300 mg/m(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/m(2) per day
Study: 795700
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (5 mg, sublingual)
Study: 1657221
Drug: Intravenous methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methylphenidate
Study: 27218476
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration EtOH (targeted BrAC = 0.100 g/dl)
Study: 19721480
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon and ribavirin treatment
Study: 18444168
Drug: Lycopene supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene supplementation (30 mg/day for 2 months)
Study: 16006090
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron saccharate Venofer (5 mg/kg injection on day 1)
Study: 11049243
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ambroxol administered)
Study: 6712466
Drug: Dexamethasone sodium
Normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone sodium phosphate (6 mg/kg) over 48 hours
Study: 29947107
Drug: Concurrent aerobic
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent aerobic and resistance exercise (CEX)
Study: 16300166
Drug: EMD 87
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 87 580 (50 mg once daily) in patients with renal dysfunction (Group 2)
Study: 16300166
Drug: EMD 87
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 87 580 (100 mg twice daily) in patients with normal renal function (Group 1)
Study: 16300166
Drug: EMD 87
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 87 580 (50 mg dose) in patients with renal dysfunction (Group 2)
Study: 16300166
Drug: EMD 87
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 87 580 (50 mg dose) in patients with normal renal function (Group 1)
Study: 18987098
Drug: Candesartan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (target dose 32 mg once daily, mean dose 24 mg)
Study: 1555751
Drug: Ursodeoxycholate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholate (600 mg/day)
Study: 4006240
Drug: Timolol (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (10-20 mg/d) for 6 weeks
Study: 4006240
Drug: Methyldopa (250-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (250-500 mg/d) for 6 weeks
Study: 16545251
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (3500 IU/d of bemiparin) subcutaneously for 6 months
Study: 26772193
Drug: Synbiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic therapy (in patients not receiving antibiotics)
Study: 14724157
Drug: Synbiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic therapy
Study: 507256
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml of bivalent split virus vaccine (A/New Jersey/76 and A/Victoria/75) intradermally
Study: 507256
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml of bivalent split virus vaccine (A/New Jersey/76 and A/Victoria/75) subcutaneously
Study: 30297351
Drug: Marine protein
Normalized name: Ascorbic Acid/Biotin/Coenzyme Q10/Grape Seed Extract/Hydrated Silica/Marine Protein/Mucopolysaccharides/Selenium/Vitamin A/Vitamin D/Vitamin E/Zinc 62 MG-50 MCG-5 MG-15 MG-60 MG-83 MCG-2417 IU-51 IU-25.5 IU-1.8 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine protein hydrolysate (MPH) 3 g per day for 12 months
Study: 17978591
Drug: Carvedilol 6.25
Normalized name: carvedilol 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 6.25 to 25 mg bid
Study: 11933177
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by radiotherapy (CT + RT)
Study: 12841537
Drug: Insulin (I)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (I)
Study: 8150016
Drug: Standard Schwarz
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Schwarz (SW) measles vaccine
Study: 29992584
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of intravenous drug use (IVDU)
Study: 22042277
Drug: PEG-L-asparaginase (2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-L-asparaginase (2500 IU/m/dose intramuscularly on days 1 and 15)
Study: 22042277
Drug: Native E.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native E. coli asparaginase (10,000 IU/m/dose intramuscularly on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26)
Study: 16409194
Drug: Grass allergen
Normalized name: orchardgrass allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass allergen tablets (75,000 SQ‐T)
Study: 14531956
Drug: Disease-modifying antirheumatic
Normalized name: ANTIRHEUMATICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying antirheumatic drugs (DMARDs), specific types and dosages not mentioned, focus on effective treatment for RA.
Study: 7997902
Drug: promethazine 0.5
Normalized name: PROMETHAZINE 0.5MG/ML/NACL INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine 0.5 mg/kg
Study: 7997902
Drug: metoclopramide 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 0.2 mg/kg
Study: 3395401
Drug: Vadocaine hydrochloride
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vadocaine hydrochloride 15 mg
Study: 3395401
Drug: Vadocaine hydrochloride
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vadocaine hydrochloride (5, 10, 15, 20, 30, 50 mg)
Study: 31869817
Drug: TMR® FAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMR® FAB 6-treatment protocol
Study: 29117576
Drug: AMH measured
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMH measured at end of chemotherapy
Study: 24626819
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d of algal docosahexaenoic acid (DHA)
Study: 16115731
Drug: LRRK 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRRK 2 G 2019 S and I 2020 T mutations evaluation in healthy controls
Study: 12106929
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine (ACh) infusion at increasing doses in the infarct-related artery (IRA)
Study: 10442370
Drug: UFT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT plus oral calcium folinate combined with epirubicin and cyclophosphamide
Study: 10442370
Drug: Continuous-infusion 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion 5-fluorouracil (5-FU)
Study: 25647628
Drug: Sunitinib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib administered at 6 p.m.
Study: 25647628
Drug: Sunitinib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib administered at 8 a.m.
Study: 25647628
Drug: Sunitinib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib administered at 4 a.m. and 4 p.m.
Study: 25647628
Drug: Sunitinib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib administered at different times (8 a.m., 1 p.m., 6 p.m.).
Study: 24369195
Drug: Fosaprepitant (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant (150 mg IV on day 1)
Study: 12765889
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) clonidine 150 microg
Study: 3567018
Drug: Carbamazepine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (400 mg) in young volunteers
Study: 3567018
Drug: Carbamazepine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (400 mg) in elderly volunteers
Study: 29856114
Drug: Insulin dosing
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dosing for both protein and carbohydrate
Study: 24752448
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (BCG and electromotive mitomycin)
Study: 24752448
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy vs BCG alone
Study: 22585285
Drug: Tolvaptan 30
Normalized name: tolvaptan 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 30 mg under fasting conditions
Study: 15764724
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone (3,000 microg/hour) administered through a metered‐dose inhaler and spacer at 10‐minute intervals for 3 hours
Study: 7846337
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone (500 mg)
Study: 10487192
Drug: Gabapentin (GBP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (GBP), 2,400 mg/day
Study: 10487192
Drug: Carbamazepine (CBZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (CBZ), mean 731 mg/day
Study: 1912554
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human erythropoietin (rhEPO) at a dose of 1,200 to 1,600 U/kg intravenously (IV) twice weekly
Study: 27180954
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) 500 mg t.i.d.
Study: 27180954
Drug: Methylcobalamin (MC)
Normalized name: MC-16
DrugBank: MC-16 (DB18005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcobalamin (MC) 0.5 mg t.i.d.
Study: 9154674
Drug: Thymostimulin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin (1 mg/kg day for the 1st week followed by once a week for 6 months)
Study: 9154674
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for COPD (Control group)
Study: 20493183
Drug: Mud bath
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud bath treatments combined with hydropinotherapy (Group A)
Study: 20493183
Drug: Mud bath
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud bath treatments without hydropinotherapy (Group B)
Study: 20493183
Drug: No spa
Normalized name: ALUMINUM CHLOROHYDRATE 25 g in 100 mL TOPICAL LIQUID [Stefano Spazio]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No spa therapies (Group C)
Study: 10425301
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (PVM) consisting of 2 cycles of the same chemotherapy in 4-week intervals.
Study: 111275
Drug: Clorgyline (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorgyline (selective MAO‐A inhibitor)
Study: 111275
Drug: Pargyline (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pargyline (selective MAO‐B inhibitor)
Study: 19228209
Drug: Delayed post‐space
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed post‐space preparation (5 days later) with Resilon/Epiphany
Study: 31703648
Drug: Per‐oral carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per‐oral carbohydrate load (preOp™) 18 and 2‐4 h before surgery (n=26)
Study: 31703648
Drug: Per‐oral carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per‐oral carbohydrate load (preOp™)
Study: 28322474
Drug: Ixekizumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (80 mg subcutaneous every 2 or 4 weeks after a 160 mg starting dose)
Study: 21839402
Drug: Etanercept (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (50 mg biweekly)
Study: 25377269
Drug: Ghrelin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin administration (3 μg/kg, twice a day)
Study: 25377269
Drug: Ghrelin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin administration (both regimens)
Study: 24088225
Drug: Lovastatin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (200 mg for 4 days)
Study: 21107813
Drug: Alpha-blocker monotherapy
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker monotherapy
Study: 21107813
Drug: Extracorporeal magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal magnetic innervations (ExMI) monotherapy
Study: 21107813
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (alpha-blocker + ExMI)
Study: 17192497
Drug: Intranasal ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketorolac
Study: 12076871
Drug: Daily high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily high dose interferon (IFN) for 6 weeks followed by standard therapy of 3 million units three times a week in combination with ribavirin for 42 weeks
Study: 10078675
Drug: Midazolam 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1.0 mg intravenously and 2.0 mg intravenously
Study: 10078675
Drug: Diazepam emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam emulsion 2.0 mg intravenously and 5.0 mg intravenously
Study: 7216144
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg naloxone i.v. followed by 1 mg FK 33‐824 i.m.
Study: 26703193
Drug: Intravenous Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Tranexamic Acid (IV TXA)
Study: 20196388
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme (ACE) inhibitors for all patients
Study: 20196388
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment protocol for severe HSP nephritis
Study: 17454701
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (nortriptyline hydrochloride)
Study: 8088068
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) starting dose 5 mg/kg
Study: 2760256
Drug: Diltiazem (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (mean daily dose 360 mg)
Study: 2760256
Drug: Combination diltiazem-nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination diltiazem-nifedipine therapy (mean daily dose 55 mg of nifedipine, 360 mg of diltiazem)
Study: 31207178
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of individual components (ertugliflozin with metformin)
Study: 1779539
Drug: Directed transport
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directed transport of antibiotics in autologous blood shadows
Study: 28398490
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
Study: 27593381
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injected (1.5 ml)
Study: 27593381
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injected (1.5 ml)
Study: 25122597
Drug: Intratympanic steroid
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic steroid injection
Study: 22645323
Drug: Steroid avoidance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid avoidance
Study: 18940487
Drug: 1 IA
Normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 IA infiltration of sodium hyaluronate (1 mL)
Study: 18940487
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of methocarbamol (380 mg) and paracetamol (300 mg) every 6 hours for 4 weeks
Study: 647173
Drug: Hypnotic induction
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic induction procedure
Study: 12585146
Drug: Yufeng Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yufeng Capsule (YFC)
Study: 1540431
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for heparin
Study: 3536765
Drug: RU 41740
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 41740 (Biostim®) 8 mg daily for 14 days
Study: 27783545
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to Patient Drug Adherence Information (PDAI)
Study: 25900517
Drug: FDC (FF
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC (FF 100 μg/LEVO 200 μg)
Study: 21042763
Drug: 180 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg/m2 irinotecan with 5-FU/leucovorin
Study: 14740952
Drug: Monovalent live
Normalized name: INFLUENZA A (H1N1) MONOVALENT LIVE VACCINE,NASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent live attenuated dengue virus vaccine candidates
Study: 14740952
Drug: Monovalent vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent vaccines (second dose at 30 or 90 days)
Study: 14740952
Drug: Tetravalent vaccine
Normalized name: DENGUE TETRAVALENT VACCINE,LIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent vaccine (single dose)
Study: 14740952
Drug: Tetravalent vaccine
Normalized name: DENGUE TETRAVALENT VACCINE,LIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent vaccine (second dose at one month)
Study: 30958356
Drug: ω3‐FA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω3‐FA supplementation (1.7g docosahexaenoic acid and 0.6g eicosapentaenoic acid daily for 6 months)
Study: 27870826
Drug: rhIGF‐1/rhIGFBP‐3, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐1/rhIGFBP‐3, administered at 250 µg/kg/d continuous i.v. infusion up to postmenstrual age 29 wk+6 d
Study: 9848295
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of luteal phase support in women with serum progesterone levels of < 60 ng/mL at 4 weeks' gestation
Study: 21813090
Drug: 0.59‐mg fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.59‐mg fluocinolone acetonide (FA) implant
Study: 15258869
Drug: 0.075 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg/kg intravenous morphine sulfate
Study: 11705788
Drug: OCP (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCP (oral contraceptives containing progesterone)
Study: 11705788
Drug: OCEP (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCEP (oral contraceptives containing progesterone and estrogen)
Study: 3050188
Drug: Ceftizoxime (CZX)
DrugBank: Ceftizoxime (DB01332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftizoxime (CZX) in various dosing regimens
Study: 31782193
Drug: Nasal Spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Spray (NS)
Study: 31782193
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) kit
Study: 27243353
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution (0.9% NaCl)
Study: 14751924
Drug: Standard-timing induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-timing induction therapy
Study: 10195532
Drug: 1.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg/kg meperidine
Study: 10195532
Drug: 1.8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg/kg meperidine